Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN.

J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9.

2.

Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod.

Berrong Z, Mkrtichyan M, Ahmad S, Webb M, Mohamed E, Okoev G, Matevosyan A, Shrimali R, Abu Eid R, Hammond S, Janik JE, Khleif SN.

Cancer Immunol Res. 2018 Feb;6(2):201-208. doi: 10.1158/2326-6066.CIR-17-0223. Epub 2018 Jan 5.

PMID:
29305519
3.

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.

Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, Gittelman RM, Yusko E, Sanders C, Robins H, Hammond SA, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Cancer Immunol Res. 2017 Sep;5(9):755-766. doi: 10.1158/2326-6066.CIR-17-0292.

PMID:
28848055
4.

Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.

Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC.

Clin Cancer Res. 2017 Jan 1;23(1):35-42. doi: 10.1158/1078-0432.CCR-16-1022. Epub 2016 Aug 2.

5.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

6.

Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.

Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Review.

PMID:
26250412
7.

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, Fleisher TA, Turner M, Urquhart NE, Wharfe GH, Figg WD, Peer CJ, Goldman CK, Waldmann TA, Morris JC.

Clin Immunol. 2014 Dec;155(2):176-87. doi: 10.1016/j.clim.2014.09.012. Epub 2014 Sep 28.

8.

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.

Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.

Blood. 2013 Mar 14;121(11):2029-37. doi: 10.1182/blood-2012-05-427773. Epub 2013 Jan 15.

9.

Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.

Blood. 2013 Jan 17;121(3):476-84. doi: 10.1182/blood-2012-08-450585. Epub 2012 Dec 3.

10.

Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.

Simone CB 2nd, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.

Blood. 2012 Aug 30;120(9):1816-9. doi: 10.1182/blood-2012-01-401349. Epub 2012 Jun 22.

11.

Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia.

Larson TA, Hu M, Janik JE, Nussenblatt RB, Morris JC, Sen HN.

Ocul Immunol Inflamm. 2012 Aug;20(4):312-4. doi: 10.3109/09273948.2012.689071. Epub 2012 May 29.

PMID:
22642512
12.

Flow cytometric immunophenotypic assessment of T-cell clonality by vβ repertoire analysis in fine-needle aspirates and cerebrospinal fluid.

Tembhare P, Yuan CM, Morris JC, Janik JE, Filie AC, Stetler-Stevenson M.

Am J Clin Pathol. 2012 Feb;137(2):220-6. doi: 10.1309/AJCPPT93VZMAREHK.

PMID:
22261447
13.

MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.

Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe ES, Calvo KR.

Haematologica. 2012 Apr;97(4):586-94. doi: 10.3324/haematol.2011.048132. Epub 2011 Nov 18.

14.

Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia.

Chen J, Petrus M, Bamford R, Shih JH, Morris JC, Janik JE, Waldmann TA.

Blood. 2012 Jan 5;119(1):137-43. doi: 10.1182/blood-2011-04-346759. Epub 2011 Nov 2.

15.

Brentuximab Vedotin (SGN-35).

Katz J, Janik JE, Younes A.

Clin Cancer Res. 2011 Oct 15;17(20):6428-36. doi: 10.1158/1078-0432.CCR-11-0488.

16.

Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.

Marti GE, Stetler-Stevenson M, Grant ND, White T, Figg WD, Tohnya T, Jaffe ES, Dunleavy K, Janik JE, Steinberg SM, Wilson WH.

Leuk Lymphoma. 2011 Dec;52(12):2284-92. doi: 10.3109/10428194.2011.589547. Epub 2011 Jul 12.

PMID:
21745173
17.

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.

J Clin Oncol. 2011 Jul 10;29(20):2787-94. doi: 10.1200/JCO.2010.33.3005. Epub 2011 May 31.

18.

Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy.

Tembhare P, Yuan CM, Xi L, Morris JC, Liewehr D, Venzon D, Janik JE, Raffeld M, Stetler-Stevenson M.

Am J Clin Pathol. 2011 Jun;135(6):890-900. doi: 10.1309/AJCPV2D1DDSGJDBW.

PMID:
21571962
19.

Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma.

Stewart DM, Ramanathan R, Mahanty S, Fedorko DP, Janik JE, Morris JC.

Acta Haematol. 2011;126(2):63-7. doi: 10.1159/000324799. Epub 2011 Apr 7.

20.

Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.

Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC.

Mol Cancer. 2011 Apr 6;10:35. doi: 10.1186/1476-4598-10-35. Review.

21.

Tumor markers in hairy cell leukemia.

Janik JE.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:69-71. doi: 10.3109/10428194.2011.568651. Epub 2011 Apr 4. Review.

PMID:
21463109
22.

Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells.

Venkataraman G, Berkowitz J, Morris JC, Janik JE, Raffeld MA, Pittaluga S.

Hum Pathol. 2011 Jul;42(7):1042-6. doi: 10.1016/j.humpath.2010.10.014. Epub 2011 Feb 11.

23.

New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE.

Clin Cancer Res. 2010 Dec 1;16(23):5608-17. doi: 10.1158/1078-0432.CCR-09-1995. Review.

24.

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.

Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR, Chen J, Sato N, Tagaya Y, Morris JC, Janik JE, Jacobson S, Waldmann TA.

Blood. 2011 Feb 10;117(6):1938-46. doi: 10.1182/blood-2010-09-305425. Epub 2010 Nov 24.

25.

Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.

Chen J, Petrus M, Bryant BR, Nguyen VP, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA.

Blood. 2010 Dec 23;116(26):5948-56. doi: 10.1182/blood-2010-04-277418. Epub 2010 Sep 21.

26.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA.

Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.

27.

Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.

Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, Stetler-Stevenson M.

Am J Clin Pathol. 2010 Apr;133(4):592-601. doi: 10.1309/AJCPS1K0OHLJYWWV.

PMID:
20231613
28.

Survivin(g) adult T-cell leukemia/lymphoma.

Janik JE, Morris JC.

Oncology (Williston Park). 2009 Dec;23(14):1256, 1261, 1266. No abstract available.

29.

Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells.

Arun I, Wulu JA, Janik JE, Jasper GA, Yuan CM, Venzon D, Stetler-Stevenson M.

Cytometry B Clin Cytom. 2010 May;78(3):169-75. doi: 10.1002/cyto.b.20507.

30.

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.

Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE.

Haematologica. 2009 Nov;94(11):1618-22. doi: 10.3324/haematol.2009.008607. Epub 2009 Jul 16.

31.

Role of chemotherapy in Hodgkin's lymphoma.

Seam P, Janik JE, Longo DL, Devita VT Jr.

Cancer J. 2009 Mar-Apr;15(2):150-4. doi: 10.1097/PPO.0b013e3181a27018. Review.

32.

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.

Blood. 2009 Jun 11;113(24):6069-76. doi: 10.1182/blood-2009-01-199679. Epub 2009 Apr 20.

33.

EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

O'Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, Pittaluga S, Raffeld M, Albert PS, Reitsma D, Kaucic K, Hammershaimb L, Waldmann TA, Janik JE.

Clin Cancer Res. 2009 Apr 1;15(7):2514-22. doi: 10.1158/1078-0432.CCR-08-1254. Epub 2009 Mar 17.

34.

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M.

Br J Haematol. 2009 Apr;145(2):173-9. doi: 10.1111/j.1365-2141.2009.07606.x. Epub 2009 Feb 19.

35.

Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.

Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ, Trepel J, Waldmann TA, Janik JE, Brady JN.

Blood. 2009 Apr 23;113(17):4016-26. doi: 10.1182/blood-2008-08-175901. Epub 2009 Jan 8.

36.

Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.

Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O'Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T.

J Clin Oncol. 2009 Jan 20;27(3):453-9. doi: 10.1200/JCO.2008.18.2428. Epub 2008 Dec 8.

37.

Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Burbelo PD, Meoli E, Leahy HP, Graham J, Yao K, Oh U, Janik JE, Mahieux R, Kashanchi F, Iadarola MJ, Jacobson S.

Retrovirology. 2008 Oct 20;5:96. doi: 10.1186/1742-4690-5-96.

38.

Receptor-directed therapy of T-cell leukemias and lymphomas.

Morris JC, Waldmann TA, Janik JE.

J Immunotoxicol. 2008 Apr;5(2):235-48. doi: 10.1080/15476910802129661. Review.

PMID:
18569395
39.

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.

Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE.

J Clin Oncol. 2008 Jun 1;26(16):2717-24. doi: 10.1200/JCO.2007.13.1391. Epub 2008 Mar 31.

40.

Mycosis fungoides and Sézary syndrome.

Hwang ST, Janik JE, Jaffe ES, Wilson WH.

Lancet. 2008 Mar 15;371(9616):945-57. doi: 10.1016/S0140-6736(08)60420-1. Review.

PMID:
18342689
41.

Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism.

Chen J, Petrus M, Bryant BR, Phuc Nguyen V, Stamer M, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA.

Blood. 2008 May 15;111(10):5163-72. doi: 10.1182/blood-2007-09-113654. Epub 2008 Mar 13.

42.

Variable osteology of the sixth cervical vertebra in relation to stellate ganglion block.

Janik JE, Hoeft MA, Ajar AH, Alsofrom GF, Borrello MT, Rathmell JP.

Reg Anesth Pain Med. 2008 Mar-Apr;33(2):102-8. doi: 10.1016/j.rapm.2007.08.013.

PMID:
18299089
43.

Bee stings--a remedy for postherpetic neuralgia? A case report.

Janik JE, Wania-Galicia L, Kalauokalani D.

Reg Anesth Pain Med. 2007 Nov-Dec;32(6):533-5.

PMID:
18035302
44.

Therapeutic immunotoxins for lymphoid malignancies: the end of the beginning.

Morris JC, Janik JE.

Leuk Lymphoma. 2007 Jun;48(6):1067-9. No abstract available.

PMID:
17577767
45.

Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.

Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, Plascjak PS, Goldman CK, Janik JE, Brechbiel MW, Waldmann TA.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8444-8. Epub 2007 May 8.

46.

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.

O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE.

Clin Cancer Res. 2007 Feb 1;13(3):958-64.

47.

Comment on "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade".

O'Mahony D, Janik JE.

J Immunol. 2006 May 1;176(9):5136; author reply 5136. No abstract available.

48.

Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.

Morris JC, Janik JE, White JD, Fleisher TA, Brown M, Tsudo M, Goldman CK, Bryant B, Petrus M, Top L, Lee CC, Gao W, Waldmann TA.

Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):401-6. Epub 2005 Dec 30.

49.

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH.

Nat Med. 2005 Sep;11(9):986-91. Epub 2005 Aug 21.

PMID:
16116429
50.

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.

Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH.

Blood. 2005 Aug 1;106(3):795-802. Epub 2005 Feb 17.

Supplemental Content

Loading ...
Support Center